A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

被引：0
|
作者：
Jian Hou
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Huisheng Ai
Jingshan Zhang
Honeylet Wortman-Vayn
Nianhang Chen
Jay Mei
Jianmin Wang
机构：
[1] Shanghai Changzheng Hospital,Department of Hematology
[2] Guangdong General Hospital,The 1st Hospital
[3] Zhejiang University,undefined
[4] Xiangya Hospital of Central South University,undefined
[5] Peking Union Medical College Hospital,undefined
[6] The 301 Hospital-Chinese PLA General Hospital,undefined
[7] Peking University Third Hospital,undefined
[8] Shanghai 6th Hospital,undefined
[9] The 1st Affiliated Hospital of Soochow University,undefined
[10] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[11] The 307 PLA Hospital,undefined
[12] Celgene Corporation,undefined
[13] Changhai Hospital,undefined
来源：
Journal of Hematology & Oncology | / 6卷
关键词：
Relapsed/Refractory Multiple Myeloma; Chinese Patients; Lenalidomide; Low-dose Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
    Fonseca, Rafael
    Alsina, Melissa
    Berdeja, Jesus
    Heitner, Stephen B.
    Morris, Christopher
    Khurana, Monica
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S241
  • [32] Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
    Moreau, Philippe
    Weisel, Katja C.
    Song, Kevin W.
    Gibson, Craig J.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2839 - 2847
  • [33] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Cai, Qian-Qian
    Wang, Chen
    Cao, Xin-Xin
    Cai, Hao
    Zhou, Dao-Bin
    Li, Jian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 325 - 330
  • [34] Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gay, Francesca
    Minnema, Monique C.
    Boccadoro, Mario
    Moreau, Philippe
    Cavenagh, Jamie
    Perrot, Aurore
    Laubach, Jacob P.
    Krejcik, Jakub
    Ahmadi, Tahamtan
    de Boer, Carla
    Chen, Diana
    Chiu, Christopher
    Schecter, Jordan M.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : E35 - E39
  • [35] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
    Grammatico, Sara
    Bringhen, Sara
    Vozella, Federico
    Siniscalchi, Agostina
    Boccadoro, Mario
    Petrucci, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
  • [36] Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study
    Terpos, Evangelos
    Repousis, Panagiotis
    Lalayanni, Chrysavgi
    Hatjiharissi, Evdoxia
    Assimakopoulou, Theodora
    Vassilopoulos, Georgios
    Pouli, Anastasia
    Spanoudakis, Emmanouil
    Michalis, Eurydiki
    Pangalis, Gerassimos
    Ntanasis-Stathopoulos, Ioannis
    Poziopoulos, Christos
    Kyrtsonis, Marie-Christine
    Pappa, Vasiliki
    Symeonidis, Argiris
    Georgopoulos, Christos
    Zikos, Panagiotis M.
    Gavriatopoulou, Maria
    Papadaki, Helen A.
    Dadakaridou, Magdalini
    Karvounis-Marolachakis, Kiki
    Katodritou, Eirini
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
  • [37] Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Kumar, Shaji K.
    Grzasko, Norbert
    Delimpasi, Sosana
    Jedrzejczak, Wieslaw W.
    Grosicki, Sebastian
    Kyrtsonis, Marie-Christine
    Spencer, Andrew
    Gupta, Neeraj
    Teng, Zhaoyang
    Byrne, Catriona
    Labotka, Richard
    Dimopoulos, Meletios A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (04) : 536 - 546
  • [38] DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Khouri, Jack
    Faiman, Beth M.
    Grabowski, Dale
    Mahfouz, Reda Z.
    Khan, Shahper N.
    Wei, Wei
    Valent, Jason
    Dean, Robert
    Samaras, Christy
    Jha, Babal K.
    Lazarus, Hillard
    Campagnaro, Erica L.
    Malek, Ehsan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Sobecks, Ronald
    Saunthararajah, Yogen
    Chew, Yap
    Orloff, Mohammed
    Reu, Frederic J.
    SEMINARS IN HEMATOLOGY, 2021, 58 (01) : 45 - 55
  • [39] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [40] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
12345